RCKT Stock Analysis: Rocket Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 374m USD | 12M Return: 14.5% | US77313F1066 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 4.85M
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Rocket Pharmaceuticals (NASDAQ: RCKT) is a late-stage biotechnology company headquartered in Cranbury, New Jersey, founded in 1999. The company focuses on developing, manufacturing, and commercializing genetic therapies for rare and devastating diseases, primarily in the United States. Its pipeline is divided into two platforms: in vivo adeno-associated viral (AAV) programs targeting cardiac conditions such as Danon disease (Phase 2), PKP2 Arrhythmogenic Cardiomyopathy (Phase 1), and BAG3 Dilated Cardiomyopathy (preclinical); and ex vivo lentiviral (LV) programs addressing hematological disorders including Leukocyte Adhesion Deficiency-I, Fanconi Anemia, and Pyruvate Kinase Deficiency. The company holds multiple license agreements with academic and research institutions, including UCL Business PLC, the Regents of the University of California, and Temple University, which underpin its gene therapy technology base. As a clinical-stage rare disease biotech, Rocket operates in a sector where therapies targeting orphan indications typically benefit from regulatory incentives such as FDA Orphan Drug Designation and Priority Review Vouchers, and where commercial success depends heavily on navigating complex manufacturing, reimbursement, and clinical development risks unique to gene-based treatments.
- FDA accepts BLA filing for LAD-I gene therapy RP-L201
- Phase 2 Danon disease RP-A501 data readout catalyst
- Rising cash burn raises going-concern dilution risk
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.40 > 0.02 and ΔFCF/TA 8.69 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.40 > 3% & CFO -170.3m > Net Income -17.2m |
| Net Debt (-199.7m) to EBITDA (7.95m): -25.12 < 3 |
| Current Ratio: 9.24 > 1.5 & < 3 |
| Outstanding Shares: last quarter (114.5m) vs 12m ago 3.15% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 2.18%; Δ -2.18% > 0%) |
| Interest Coverage Ratio: -0.83 > 6 (EBIT TTM -3.90m / Interest Expense TTM 4.73m) |
| A: 0.61 (Total Current Assets 289.6m - Total Current Liabilities 31.3m) / Total Assets 423.1m |
| B: -3.23 (Retained Earnings -1.37b / Total Assets 423.1m) |
| C: -0.01 (EBIT TTM -3.90m / Avg Total Assets 422.0m) |
| D: 6.80 (Book Value of Equity 368.8m / Total Liabilities 54.3m) |
| Altman-Z'' = 0.56 = B |
As of August 17, 2026, the stock is trading at USD 3.47 with a total of 1,159,036 shares traded. Over the past week, the price has changed by -3.88%, over one month by +1.76%, over three months by +13.03% and over the past year by +14.52%.
Current recommended Stop Loss: 2.90 (which is 16.4% or 2.9 ATR below the current price).
Rocket Pharmaceuticals has received a consensus analysts rating of 4.61. Therefore, it is recommended to buy RCKT.
- StrongBuy: 12
- Buy: 5
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 8.8 | 154.8% |
P/B = 1.6743
Revenue TTM = 0.0 USD
EBIT TTM = -3.90m USD
EBITDA TTM = 7.95m USD
Long Term Debt = 21.8m USD (estimated: total debt 24.8m - short term 2.98m)
Short Term Debt = 2.98m USD (from shortTermDebt, last quarter)
Debt = 24.8m USD (from shortLongTermDebtTotal, last quarter) (leases 24.8m already included)
Net Debt = -199.7m USD (calculated: Debt 24.8m - CCE 224.5m)
Enterprise Value = 174.6m USD (374.3m + Debt 24.8m - CCE 224.5m)
Interest Coverage Ratio = -0.83 (Ebit TTM -3.90m / Interest Expense TTM 4.73m)
EV/FCF = -1.02x (Enterprise Value 174.6m / FCF TTM -170.4m)
FCF Yield = -97.58% (FCF TTM -170.4m / Enterprise Value 174.6m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 11.0m) / Revenue TTM)
Tobins Q-Ratio = 0.41 (Enterprise Value 174.6m / Total Assets 423.1m)
Interest Expense / Debt = 19.07% (Interest Expense 4.73m / Debt 24.8m)
Taxrate = 6.54% (8.62m / 131.8m)
NOPAT = -3.65m (EBIT -3.90m * (1 - 6.54%)) [loss with tax shield]
Current Ratio = 9.24 (Total Current Assets 289.6m / Total Current Liabilities 31.3m)
Debt / Equity = 0.07 (Debt 24.8m / totalStockholderEquity, last quarter 368.8m)
Debt / EBITDA = -25.12 (Net Debt -199.7m / EBITDA 7.95m)
Debt / FCF = 1.17 (negative FCF - burning cash) (Net Debt -199.7m / FCF TTM -170.4m)
Total Stockholder Equity = 299.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -4.09% (Net Income -17.2m / Total Assets 423.1m)
RoE = -5.76% (Net Income TTM -17.2m / Total Stockholder Equity 299.4m)
RoCE = -1.21% (EBIT -3.90m / Capital Employed (Equity 299.4m + L.T.Debt 21.8m))
RoIC = -0.92% (negative operating profit) (NOPAT -3.65m / Invested Capital 394.8m)
WACC = 11.45% (E(374.3m)/V(399.1m) * Re(11.03%) + D(24.8m)/V(399.1m) * Rd(19.07%) * (1-Tc(0.07)))
Discount Rate = 11.03% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.65 | Cagr: 9.40%
[DCF] Fair Price = unknown (Cash Flow -170.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -4.0 | # QB: -1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.40 | Chg30d=+6.40% | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=-0.10 | Chg30d=+86.30% | Revisions=+17% | GrowthEPS=+94.8% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.27 | Chg30d=-7.67% | Revisions=-17% | GrowthEPS=-1137.4% | GrowthRev=+991.2%
[Analyst] Revisions Ratio: +0% (up=4, down=4)